Clinical Research Directory
Browse clinical research sites, groups, and studies.
Arginine Replacement Therapy in COVID-19
Sponsor: Emory University
Summary
This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed at the Children's Healthcare of Atlanta, Arthur M. Blank Hospital. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.
Official title: Prospective Open-Label Pilot Study of Arginine Replacement Therapy in Children Hospitalized With COVID-19
Key Details
Gender
All
Age Range
3 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2024-01-08
Completion Date
2027-06
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
Arginine Hydrochloride
Arginine will be infused based on the manufacturer's instructions (R-Gene 10, Pfizer), over 30 minutes. However, rates may be slowed to over 60 minutes for patients experiencing symptoms of flushing, nausea, vomiting, or headache at the research team's discretion. Pediatric doses will be drawn up by the pharmacy.
Locations (1)
Children's Healthcare of Atlanta (CHOA), Arthur M. Blank
Atlanta, Georgia, United States